UroGen Pharma Ltd. (URGN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

UroGen Pharma Ltd. (URGN) Healthcare & Pipeline Overview

UroGen Pharma Ltd. is a biotechnology firm specializing in non-surgical solutions for specialty cancers and urothelial diseases, leveraging its proprietary RTGel technology for improved drug delivery. The company focuses on advancing pipeline candidates like UGN-102 in Phase III trials for non-muscle invasive urothelial cancer, aiming to address significant unmet medical needs within the oncology space.

What Is the Investment Thesis for URGN?

UroGen Pharma Ltd. presents an investment thesis centered on its proprietary RTGel technology and a pipeline addressing significant unmet needs in urothelial cancers. The company's commercialized product, Jelmyto, for low-grade upper tract urothelial carcinoma, demonstrates the efficacy of its drug delivery platform, contributing to a robust gross margin of 89.9%. Key growth catalysts include the ongoing Phase III clinical trials for UGN-102, targeting low-grade non-muscle invasive bladder cancer and additional indications for LG-UTUC. Positive outcomes from these trials could significantly expand UroGen's addressable market and revenue streams. Furthermore, the development of UGN-301 for high-grade non-muscle invasive bladder cancer represents a substantial future opportunity, potentially unlocking a larger market segment. Strategic partnerships with Allergan, Agenus, and MD Anderson validate its technology and broaden its development capabilities. However, the company operates with a negative profit margin of -94.8%, reflecting its stage as a biotechnology firm heavily invested in R&D. Future profitability hinges on successful clinical trial completion, regulatory approvals, and sustained market adoption of its pipeline products. The high beta of 1.59 indicates higher volatility relative to the market, typical for a biotechnology company.

Based on FMP financials and quantitative analysis

URGN Key Highlights

• Market Capitalization: UroGen Pharma Ltd. maintains a market capitalization of $2.02B, reflecting investor valuation of its commercial product and pipeline potential in the biotechnology sector.
• Gross Margin: The company reports a strong gross margin of 89.9%, indicating efficient cost management relative to its revenue from commercialized products like Jelmyto.
• Profit Margin: UroGen Pharma Ltd. currently operates with a profit margin of -94.8%, characteristic of a biotechnology company in the development phase with significant R&D expenditures.
• Beta: With a Beta of 1.59, UroGen Pharma Ltd. exhibits higher volatility compared to the broader market, which is common for companies in the clinical-stage biotechnology industry.
• Workforce: The company employs 234 individuals, a focused team dedicated to advancing its research, development, and commercialization efforts in specialty cancers and urothelial diseases.

Who Are URGN's Competitors?

URGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are URGN's Key Strengths?

• Proprietary RTGel drug delivery technology.
• Commercialized product (Jelmyto) with strong gross margin (89.9%).
• Advanced clinical pipeline with UGN-102 in Phase III.
• Strategic collaborations with Allergan, Agenus, and MD Anderson.

What Are URGN's Weaknesses?

• Negative profit margin (-94.8%) due to R&D intensity.
• Reliance on successful clinical trial outcomes for future growth.
• High operating expenses typical of a biotechnology company.
• Limited product portfolio beyond Jelmyto currently.

What Could Drive URGN Stock Higher?

• Announcement of top-line data from the UGN-102 Phase III clinical trials for low-grade non-muscle invasive bladder cancer, expected to provide critical insights into the drug's efficacy and safety profile.
• Potential regulatory submissions and subsequent approvals for UGN-102 in new indications, which could significantly expand the addressable market for UroGen Pharma.
• Continued market penetration and sales growth of Jelmyto for low-grade upper tract urothelial carcinoma, driven by increased physician awareness and patient adoption.
• Progress in the clinical development of UGN-301 for high-grade non-muscle invasive bladder cancer, including initiation of later-stage trials or release of preliminary data.
• Further advancements or new agreements stemming from strategic collaborations with partners like Allergan, Agenus, or MD Anderson, potentially leading to new pipeline candidates or expanded market opportunities.

What Are the Key Risks for URGN?

• Financial-distress signal — its Altman Z-Score of -2.32 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of UGN-102 or UGN-301 to meet primary or secondary endpoints in ongoing or future clinical trials, which could lead to delays, abandonment, or significant devaluation of the pipeline.
• Regulatory hurdles and potential delays or non-approvals from health authorities (e.g., FDA, EMA) for pipeline candidates, impacting the timeline and ability to commercialize new products.
• Intense competition from existing treatments, generic alternatives, or new therapies developed by larger pharmaceutical companies, potentially limiting market share and pricing power for UroGen's products.
• Significant capital requirements for research and development, clinical trials, and commercialization efforts, which could lead to further dilution through equity financing if profitability is not achieved.
• Challenges in market adoption and reimbursement for novel therapies, even after approval, if healthcare providers or payers are slow to integrate new treatments or if pricing is deemed unfavorable.

What Are the Growth Opportunities for URGN?

• Expansion of UGN-102 Indications and Market Adoption: UGN-102, currently in Phase III clinical trials, targets low-grade non-muscle invasive bladder cancer (LG-NMIBC) and additional indications for low-grade upper tract urothelial carcinoma (LG-UTUC). The global market for bladder cancer treatment is projected to reach over $10 billion by 2027, with NMIBC representing a significant portion. Successful trial completion and regulatory approval for LG-NMIBC could substantially expand UroGen Pharma's addressable patient population beyond its current LG-UTUC market, driving significant revenue growth within the next 3-5 years. The non-surgical nature of UGN-102 offers a compelling alternative to existing invasive procedures.
• Development and Commercialization of UGN-301: UroGen Pharma is developing UGN-301 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), a more aggressive form of the disease with a high recurrence rate and limited effective treatment options. The HG-NMIBC market represents a substantial unmet medical need, with a global market size projected to be several billion dollars. Successful progression through clinical trials and eventual commercialization of UGN-301 could position UroGen Pharma as a leader in this critical segment, offering a novel therapeutic approach within a 5-7 year timeline, significantly diversifying its product portfolio and revenue streams.
• Leveraging the RTGel Technology Platform: The proprietary RTGel technology, a polymeric biocompatible and reverse thermal gelation hydrogel, is a foundational asset for UroGen Pharma. Beyond Jelmyto and its pipeline candidates, this platform has the potential for broader application in drug delivery across various therapeutic areas, not just urothelial cancers. Licensing opportunities or internal development of new drug candidates utilizing RTGel could unlock substantial value. The global drug delivery systems market is anticipated to exceed $2 trillion by 2028, indicating vast potential for a versatile platform like RTGel to enhance drug profiles and expand into new therapeutic indications over the long term (5-10 years).
• Strategic Partnerships and Collaborations: UroGen Pharma's existing license agreement with Allergan Pharmaceuticals International Limited for RTGel and clostridial toxins, and its collaboration with Agenus Inc. for intravesical delivery of cancer treatments, represent significant growth avenues. These partnerships validate UroGen's technology and provide access to broader development expertise and potential market reach without solely relying on internal R&D. Further strategic alliances, potentially involving co-development or regional commercialization agreements, could accelerate market penetration and reduce financial risk, particularly in expanding into new geographic markets or therapeutic segments within the next 2-5 years.
• Increased Market Adoption and Geographic Expansion of Jelmyto: Jelmyto, currently approved for low-grade upper tract urothelial carcinoma, has demonstrated its efficacy and market potential. Continued efforts to increase physician awareness, patient access, and reimbursement coverage for Jelmyto can drive further sales growth. While the initial focus is on established markets, potential geographic expansion into Europe or Asia, subject to regulatory approvals, could significantly broaden its revenue base. The global market for LG-UTUC treatments, while niche, offers opportunities for sustained growth as awareness of non-surgical options increases, with continued market penetration expected over the next 2-4 years.

What Opportunities Does URGN Have?

• Expansion of UGN-102 indications to broader NMIBC market.
• Development and commercialization of UGN-301 for high-grade NMIBC.
• Leveraging RTGel platform for new therapeutic applications or partnerships.
• Potential geographic expansion for Jelmyto and future products.

What Threats Does URGN Face?

• Clinical trial failures or delays.
• Regulatory hurdles and potential non-approvals.
• Intense competition from existing and emerging treatments.
• Market adoption challenges for novel therapies.
• Patent expirations or intellectual property challenges.

What Are URGN's Competitive Advantages?

• Proprietary RTGel Technology: A unique, polymeric biocompatible hydrogel platform enabling sustained and localized drug delivery, differentiating its product pipeline.
• Specialized Focus: Deep expertise and targeted development in the niche area of urothelial cancers, allowing for focused R&D and market penetration.
• First-in-Class Approvals: Jelmyto's approval as the first non-surgical treatment for LG-UTUC establishes a strong market position and regulatory precedent.
• Extensive Clinical Pipeline: A robust pipeline with lead candidates in late-stage clinical trials (UGN-102) and early-stage development (UGN-301) for significant unmet needs.
• Strategic Partnerships: Collaborations with established pharmaceutical companies and research institutions validate technology and expand development capabilities.

What Does URGN Do?

UroGen Pharma Ltd., established in 2004 and headquartered in Princeton, New Jersey, operates as a biotechnology company dedicated to the development and commercialization of innovative solutions for specialty cancers and various urothelial diseases. The company's core technological asset is RTGel, a proprietary polymeric biocompatible and reverse thermal gelation hydrogel. This advanced hydrogel is designed to enhance the therapeutic profiles of existing drugs by enabling sustained and localized drug delivery, thereby potentially improving efficacy and reducing systemic side effects. UroGen Pharma's flagship commercial product is Jelmyto (mitomycin) for pyelocalyceal solution, approved for the treatment of low-grade upper tract urothelial carcinoma (LG-UTUC). This product represents a significant advancement by offering a non-surgical treatment option for a rare and challenging cancer. Beyond its commercialized product, the company maintains a robust development pipeline. Its lead product candidate, UGN-102, is currently undergoing Phase III clinical trials. UGN-102 is being investigated for the treatment of several forms of non-muscle invasive urothelial cancer, including both low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. Further expanding its therapeutic reach, UroGen Pharma is also actively developing UGN-301, a promising candidate aimed at addressing high-grade non-muscle invasive bladder cancer, a condition with substantial unmet medical needs. The company strategically enhances its capabilities and market presence through various collaborations and licensing agreements. Notable partnerships include a license agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of pharmaceutical products incorporating RTGel with clostridial toxins. Additionally, UroGen Pharma has a collaboration with Agenus Inc. to develop and commercialize Agenus products for urinary tract cancers via intravesical delivery, and a strategic research collaboration with MD Anderson to advance investigational treatments for high-grade bladder cancer. These alliances underscore UroGen Pharma's commitment to innovation and its multi-faceted approach to tackling complex urologic oncology challenges.

What Products and Services Does URGN Offer?

• Develops and commercializes novel solutions for specialty cancers and urothelial diseases.
• Utilizes a proprietary RTGel technology for improved drug delivery.
• Offers Jelmyto, a pyelocalyceal solution for low-grade upper tract urothelial carcinoma.
• Conducts Phase III clinical trials for UGN-102, targeting non-muscle invasive urothelial cancer.
• Develops UGN-301 for high-grade non-muscle invasive bladder cancer.
• Engages in strategic licensing and research collaborations with pharmaceutical partners like Allergan and Agenus, and institutions like MD Anderson.
• Focuses on non-surgical and localized treatment options for urologic oncology.

How Does URGN Make Money?

• Generates revenue from the sales of its commercialized product, Jelmyto, for low-grade upper tract urothelial carcinoma.
• Aims to generate future revenue from the successful development, regulatory approval, and commercialization of pipeline products like UGN-102 and UGN-301.
• Potentially earns licensing fees, milestone payments, and royalties from strategic partnerships involving its RTGel technology or pipeline assets.
• Invests significantly in research and development to discover and advance new therapeutic candidates.

What Industry Does URGN Operate In?

UroGen Pharma Ltd. operates within the dynamic and research-intensive Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by significant R&D investments, long development cycles, and stringent regulatory pathways. The company specifically targets urothelial diseases and specialty cancers, a niche but high-value segment within oncology. Market trends indicate a growing demand for less invasive and more targeted cancer therapies, particularly for conditions like bladder cancer, which has a high recurrence rate. UroGen Pharma's proprietary RTGel technology positions it uniquely by offering improved drug delivery for existing and novel compounds, potentially enhancing patient outcomes and convenience. The competitive landscape includes established pharmaceutical companies with existing oncology portfolios and other biotechnology firms developing competing treatments. UroGen Pharma differentiates itself through its focus on non-surgical, localized treatments and its innovative hydrogel platform, aiming to capture market share by addressing specific unmet needs in a specialized therapeutic area.

Who Are URGN's Key Customers?

• Urologists and oncologists specializing in urothelial cancers.
• Hospitals and cancer treatment centers.
• Patients diagnosed with low-grade upper tract urothelial carcinoma (for Jelmyto).
• Future patients with non-muscle invasive bladder cancer (for pipeline candidates).

FY2026 estForward Outlook

Wall Street analysts project UroGen Pharma Ltd. revenue of about $276.5M for fiscal 2026, with EPS near $-0.70. The estimate reflects 6 contributing analysts.

F-Score 2/9Financial Health

UroGen Pharma Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.32 places it in the distress zone, a signal of elevated financial risk.

ROE 122%Key Financial Metrics

Return on equity for UroGen Pharma Ltd. stands at 121.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -52.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.2%, the inverse of the P/E and a quick read on earnings relative to price.

UroGen Pharma Ltd. (URGN) Valuation Context

Valued at $2.02B, URGN is classified as a mid-cap stock. Relative to its peer group, URGN's quantitative score of 11/100 is below the peer average of 86/100.

Company Profile

UroGen Pharma Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Elizabeth Barrett. URGN has traded publicly since 2017.

URGN Financials

URGN Latest News

URGN Analyst Consensus

URGN MoonshotScore

Common Questions About URGN (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources